CORFLOW-THERAPEUTICS
19.5.2023 10:01:25 CEST | Business Wire | Press release
CorFlow Therapeutics AG, a clinical-stage company that has developed the world’s first combined system for diagnostic assessment and therapy delivery to address coronary microvascular obstruction (MVO), has announced the interim positive results of its MOCA I (Microvascular Obstruction with CoFI System Assessment) study at EuroPCR in Paris, France. The first-in-human study aims to evaluate the safety and feasibility of a novel real-time catheter-based system to detect MVO immediately after primary percutaneous coronary intervention (PPCI) and deliver timely therapeutic intracoronary agents. The data set presented in a EuroPCR Late Breaking Trial session included 30 patients with an ST elevation myocardial infarction (STEMI), the most severe type of heart attack.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230519005005/en/
CorFlow has developed a next-generation fully-integrated CoFI system, which will be utilized in the upcoming pivotal trial prior to be commercially available. It is an investigational device limited by federal law to investigational use and is not available for commercial distribution yet. (Photo: Business Wire)
The system outputs a novel pressure parameter (PCoFI) for detection of MVO, which was evaluated for correlation with cardiac MRI measured MVO, considered the reference standard. For the patients who had the CoFI diagnostic sequence, the essential results of the study showed that the system provided a sensitivity of 95%, specificity of 91%, and AUC of 0.94 for the ability to detect MVO measured by cardiac MRI. The CoFI device and procedure were deemed safe with no device-related deaths, flow-limiting dissections, or thrombotic events at 30 days, as adjudicated by an independent Clinical Events Committee.
The MOCA I study, presented by Professor Dr. Marco Valgimigli, Deputy Chief of Cardiology at the Cardiocentro Ticino Institute in Lugano, Switzerland, suggests that it may now be possible to have accurate, early detection which can lead to targeted treatment for these high-risk patients. Finally, we may be able to detect MVO with confidence, directly at the end of a primary PCI. This is significant. These are important findings that call for further research with this technology.”
Current interventional cardiology technologies, addressing the larger coronary arteries, have been instrumental in saving patients from death and complications after a heart attack, reducing short term mortality over the last several decades. Yet for many patients, longer term outcomes are still poor despite current standard of care treatment. MVO, which is found to be in more than 50% of heart attack patients, has been shown to be the single most powerful prognostic indicator for negative outcomes for these patients, including heart failure and death. Heart disease remains the leading cause of death worldwide, with more than 85% of these due to heart attacks and strokes. Multiple peer-reviewed studies suggest that addressing these blockages in the coronary microcirculation could reduce this global burden.
“The data presented from the MOCA I study with the CorFlow system is very encouraging for our community of cardiologists, who are increasingly recognizing MVO and microvascular disease as a next frontier to improve outcomes in our field,” stated Dr. Azeem Latib of Montefiore Medical Center, New York City, USA. “This emerging area is in its early days, but we can agree that a significant step forward is made by being able to diagnose these patients in the cath lab. With such a technology, we can imagine that many concomitant therapy options can soon be evaluated, since it is now clear that treating only the larger vessels is not enough.”
“Real-time catheter-based MVO detection can provide healthcare professionals with valuable information about the extent and severity of the heart attack, which can inform immediate treatment decisions to impact patient outcomes," stated Paul Mead, CEO of CorFlow. “The CoFI System can be a game-changer as it is the first of its kind and can potentially revolutionize the field, which is ripe for innovation that makes a difference. The ‘next big thing’ in interventional cardiology should be driven by where the largest positive impact in outcomes can be made, and it is hard to imagine a clearer target in this regard than STEMI patients with MVO, the first indication we pursued. MOCA I shows that we can, and will, do better for these patients.”
About the CorFlow CoFI System
The Controlled Flow Infusion (CoFI) System is designed for diagnostic assessment of the coronary microcirculation in the cath lab, and to be a platform for controlled infusion of physician-specified diagnostic and therapeutic agents into the microcirculation. The CoFI System uses proprietary software algorithms to detect microvascular obstruction (MVO) and potentially other conditions related to microvascular function. The system the company plans to bring to the market is comprised of a next generation console, an advanced proprietary catheter with a pressure sensor wire, and single use infusion cassette. In addition to the primary clinical target addressing heart attack patients, the company intends to pursue other indications in both coronary and broader vascular use cases with the technology which are covered by broad patent families.
About CorFlow
CorFlow Therapeutics AG, a venture-backed company headquartered in Switzerland, is advancing medical technology and cardiology in an area many are calling "the next frontier" to improve clinical outcomes for people with heart attacks and coronary artery disease. Two of the founders of the company are renowned interventional cardiologists, Dr. Rob Schwartz and Dr. Martin Rothman, who discovered acute unmet needs over decades of clinical practive. The company is currently raising its Series B round of funding to pursue its mission to save lives and achieve future milestones. The company is continuing to enroll patients in the ongoing European "MOCA I" clinical trial of the CoFI System and is working toward US study submissions for clinical trials and commercialization of its technology. www.corflowinc.com
The CoFI-System is not approved in the United States of America. It is an investigational device limited by federal law to investigational use and is not available for commercial distribution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005005/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdspartneren Milestone Technologies19.3.2026 19:02:00 CET | Pressemeddelelse
Andersen Consulting fortsætter med at styrke sin platform for digital transformation med tilføjelsen af samarbejdspartneren Milestone Technologies, der er en veletableret global leverandør af it-services og digitale løsninger med base i USA. Milestone Technologies blev grundlagt i 1997 og leverer omfattende teknologi- og outsourcingløsninger, der spænder over digitale arbejdspladstjenester, cloud- og infrastrukturstyring, data, AI og automatisering, apps og digital engineering, business process outsourcing samt implementering af platforme som ServiceNow og Salesforce. Med hovedkontor i Fremont, Californien, opererer Milestone i 35 lande på globalt plan og samarbejder med nogle af verdens største virksomheder. Virksomhedens integrerede leveringsmodel gør det muligt for kunder at transformere deres it-drift, øge serviceeffektiviteten og skalere teknologiske økosystemer gnidningsfrit over hele verden. "Milestone Technologies er en medarbejderfokuseret organisation, der leverer målbare for
Klarna Card reaches 5 million active customers19.3.2026 15:31:00 CET | Press release
Klarna, the global digital bank and payments provider, today announced that the Klarna Card has reached 5 million active customers globally, underscoring rapid adoption as consumers shift towards new forms of payment which provide more control over day-to-day money management. The card draws from the customer's own funds for everyday spending, with the option to spread the cost of a specific purchase, like a large appliance or a flight, when it makes sense to do so. The result is a card that offers genuine spending control without the long-term debt obligations that come with traditional credit cards. The card’s growth is reinforced by Klarna’s membership program. The program offers premium perks such as airport lounge access, travel insurance, and lifestyle subscriptions — without requiring users to take on debt, meet spending thresholds, or revolve balances. By separating everyday spending from rewards, Klarna is challenging the strings-attached model legacy banks have long relied on
Stonebranch Releases 2026 Global State of IT Automation Report, Revealing Orchestration as the Missing Link for AI Adoption and Trust19.3.2026 14:30:00 CET | Press release
New research shows hybrid IT orchestration, automation-as-a-service, and WLA investments are accelerating as AI workflow deployment scales across the enterprise. Stonebranch, a leading provider of service orchestration and automation solutions, today released its annual 2026 Global State of IT Automation Report, the company’s most comprehensive research study to date. Based on responses from 402 IT automation professionals spanning C-suite executives to individual contributors across North America, EMEA, Latin America, and APAC, the report provides a detailed, data-driven portrait of how enterprises are investing in, deploying, and deriving value from IT automation in 2026. “This year’s findings highlight an important shift in how organizations approach automation,” said Giuseppe Damiani, CEO of Stonebranch. “Organizations are now building automation as strategic infrastructure — a governed, scalable foundation that spans hybrid environments, operationalizes AI, and delivers automation
Perma-Pipe Accelerates Growth with New U.S. Northeast Facility Investment to serve Artificial Intelligence Data Center customers, Provides Middle East Operations’ Update and Concludes the Board’s Review of Strategic Alternatives19.3.2026 14:00:00 CET | Press release
Perma-Pipe International Holdings, Inc. (the “Company”) today announced a strategic expansion initiative focused on accelerating growth through entry into the high-demand U.S. Northeast region. The Company is positioning itself to capitalize on the rapidly expanding Artificial Intelligence (“AI”)-driven data center market in both the United States and international markets while continuing to reinforce its leadership in critical infrastructure solutions. As part of this growth strategy, Perma-Pipe will prioritize investments aimed at expanding its presence in the rapidly evolving AI data center sector. The initiative reflects the Company’s long-term commitment to supporting next-generation technology infrastructure and strengthening its position in the global energy, industrial, and infrastructure markets. Expansion in the U.S. Northeast President & Chief Executive Officer, Saleh Sagr said, “We are excited to announce the expansion of our operations with a new facility in the Northeast
Armis Launches First-of-Its-Kind Benchmark Report Warning of Critical Security Gaps in AI-Native Development19.3.2026 13:00:00 CET | Press release
Research reveals 100% of leading generative AI models fail to generate secure code for critical development scenarios Armis, the cyber exposure management & security company, is warning that the rapid enterprise adoption of AI-native development is outpacing critical security safeguards, leaving organizations exposed to systemic vulnerabilities. New research from Armis Labs’ Trusted Vibing Benchmark Report, which evaluates 18 leading generative AI models across 31 test scenarios, reveals a 100% failure rate in generating secure code. These vulnerabilities are most prevalent in high-risk areas like memory buffer overflows, design file uploads and authentication systems. Therefore, organizations should immediately implement AI-native application security controls to reduce risk. “The era of vibe coding is here, but speed should not come at the cost of security,” said Nadir Izrael, CTO and Co-Founder of Armis. “Our research finds that the worst offenders are the same ones selling security
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom